4 completed. 4 Phase 2.
By phase and status
Follow SEL: new trials by email Literature Review of SEL trials Research Report on SEL
Trials (filtered) newest first · largest first
All 4 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease
SEL, Placebo - Diabetic Kidney Disease | Phase 2 | Completed | 384 | 2019-07-24 | 2022-12-21 |
Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
SEL, FIR, CILO - Nonalcoholic Steatohepatitis | Phase 2 | Completed | 395 | 2018-03-21 | 2020-12-03 |
Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)
SEL, FIR, CILO - Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver Disease (NAFLD) | Phase 2 | Completed | 220 | 2016-06-13 | 2022-03-16 |
Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3
SEL, SIM - Non-Alcoholic Steatohepatitis (NASH) | Phase 2 | Completed | 72 | 2015-06-08 | 2019-06-26 |
Conditions studied
Non-alcoholic Fatty Liver Disease (3) · Diabetic Nephropathies (1) · Fibrosis (1)
Sponsors
Gilead Sciences (4)
Countries
United States (4) · Canada (3) · New Zealand (3) · Australia (2) · Hong Kong (1) · Japan (1) · Puerto Rico (1)
Results publications
PMID 33169409, PMID 34999207, PMID 39018154
NIH funding
2018 (1)